Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Want to see ELVN full AI Analyst Report?
Total Valuation
Enliven Therapeutics has a market cap or net worth of $2.55B. The enterprise value is $2.44B.
Market Cap$2.55B
Enterprise Value$2.44B
Share Statistics
Enliven Therapeutics has 60,904,945 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,904,945
Owned by Insiders16.37%
Owned by Institutions7.51%
Financial Efficiency
Enliven Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -26.01%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-26.01%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee0.00
Profits Per Employee-1.67M
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enliven Therapeutics is ―. Enliven Therapeutics’s PEG ratio is 2.65.
PE Ratio―
PS Ratio0.00
PB Ratio1.90
Price to Fair Value1.90
Price to FCF-12.38
Price to Operating Cash Flow-40.53
PEG Ratio2.65
Income Statement
In the last 12 months, Enliven Therapeutics had revenue of 0.00 and earned -103.69M in profits. Earnings per share was -1.83.
Revenue0.00
Gross Profit-263.00K
Operating Income-119.66M
Pretax Income-103.69M
Net Income-103.69M
EBITDA-119.39M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -65.47M and capital expenditures -138.00K, giving a free cash flow of -65.60M billion.
Operating Cash Flow-65.47M
Free Cash Flow-65.60M
Free Cash Flow per Share-1.08
Dividends & Yields
Enliven Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change151.94%
50-Day Moving Average39.71
200-Day Moving Average26.34
Relative Strength Index (RSI)53.20
Average Volume (3m)806.45K
Important Dates
Enliven Therapeutics upcoming earnings date is Aug 19, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Enliven Therapeutics as a current ratio of 28.66, with Debt / Equity ratio of 0.07%
Current Ratio28.66
Quick Ratio28.66
Debt to Market Cap<0.01
Net Debt to EBITDA0.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Enliven Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Enliven Therapeutics EV to EBITDA ratio is -6.48, with an EV/FCF ratio of -10.99.
EV to Sales0.00
EV to EBITDA-6.48
EV to Free Cash Flow-10.99
EV to Operating Cash Flow-11.01
Balance Sheet
Enliven Therapeutics has $452.40M in cash and marketable securities with $302.00K in debt, giving a net cash position of $452.10M billion.
Cash & Marketable Securities$452.40M
Total Debt$302.00K
Net Cash$452.10M
Net Cash Per Share$7.42
Tangible Book Value Per Share$8.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Enliven Therapeutics is $57.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$57.14
Price Target Upside18.78% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast13.79%